CC BY-NC-ND 4.0 · Laryngorhinootologie 2022; 101(S 02): S211
DOI: 10.1055/s-0042-1746704
Abstracts | DGHNOKHC
Head-Neck-Oncology: Medicinal tumor therapy

Significance of initial blood parameters on total cumulative dose of cisplatin in HNSCC

Frederic Jungbauer
1   Universitätsklinikum Mannheim, Universitätsklinik für Hals-Nasen-Ohrenheilkunde, Kopf- und Halschirurgie Mannheim
,
Lena Huber
1   Universitätsklinikum Mannheim, Universitätsklinik für Hals-Nasen-Ohrenheilkunde, Kopf- und Halschirurgie Mannheim
,
Sonja Ludwig
1   Universitätsklinikum Mannheim, Universitätsklinik für Hals-Nasen-Ohrenheilkunde, Kopf- und Halschirurgie Mannheim
,
Kirsten Merx
2   Universtitätsklinikum Mannheim, III. Medizinische Klinik (Hämatologie und Internistische Onkologie) Mannheim
,
Nicole Rotter
1   Universitätsklinikum Mannheim, Universitätsklinik für Hals-Nasen-Ohrenheilkunde, Kopf- und Halschirurgie Mannheim
,
Beatrice Walter
1   Universitätsklinikum Mannheim, Universitätsklinik für Hals-Nasen-Ohrenheilkunde, Kopf- und Halschirurgie Mannheim
,
Lena Zaubitzer
1   Universitätsklinikum Mannheim, Universitätsklinik für Hals-Nasen-Ohrenheilkunde, Kopf- und Halschirurgie Mannheim
,
Anne Lammert
1   Universitätsklinikum Mannheim, Universitätsklinik für Hals-Nasen-Ohrenheilkunde, Kopf- und Halschirurgie Mannheim
› Author Affiliations
› Further Information
Also available at
 

For squamous cell carcinoma of the head and neck (HNSCC), cisplatin is used as primary or adjuvant (radio)chemotherapeutic agent. For an optimal outcome, the highest possible cumulative total dose of cisplatin (CDC) is aimed for. The selection of the scheme is patient-specific, but the factors for the selection of the optimal scheme have not yet been conclusively elucidated. The aim of this study was to find correlations between initial laboratory values and the cumulative total dose of cisplatin to provide support for the selection of the appropriate chemotherapy regimen. In this retrospective study, blood parameters, namely glomerular filtration rate (GFR), hemoglobin, albumin, leucocyte, erythrocyte and platelet count, over the course of time of 79 patients (median age 64 years, range 33-80 years) with HNSCC who had received chemotherapy with cisplatin in our clinic between 2018 and 2021 were evaluated. Significant positive correlations were seen for total cumulative dose of cisplatin with initial GFR (p=0.001, Pearson's r=0.364), initial hemoglobin (p=0.035, r=0.237), initial erythrocyte (p=0.002, r=0.337), and initial albumin (p=0.002, r=0.337). There were no significant correlations for initial leucocyte or platelet count, nor for the age of the patients. It can be assumed that the correlations of hemoglobin and erythrocyte values are also due to the regular function of the kidneys. High renal functionality is associated with high CDC and may therefore be considered a predictive factor. Because of their high dynamic range, platelets and leukocytes are not suitable for estimating subsequent CDC, nor is the calendrical age of the patient.



Publication History

Article published online:
24 May 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany